
    
      To evaluate the security and the relapse-free survival time/rate(1,2,3 yrs) of perioperative
      chemotherapy with ECX (epirubicin + cisplatin + capecitabine) and XP (capecitabine +
      cisplatinï¼‰in advanced gastric cancer
    
  